Get the Stockscreener App
0.2643
6.14%
-0.0127
In 8 Bio Inc stock is traded at $0.2643, with a volume of 322.11K.
It is down -6.14% in the last 24 hours and down -24.64% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$0.277
Open:
$0.28
24h Volume:
322.11K
Relative Volume:
0.42
Market Cap:
$20.08M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-0.3524
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
+1.64%
1M Performance:
-24.64%
6M Performance:
-63.33%
1Y Performance:
-78.69%
1-Day Range:
$0.256
$0.2812
1-Week Range:
$0.2352
$0.30
52-Week Range:
$0.217
$1.74
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
0.26 | 20.08M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.66 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.52 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.67 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.46 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Mustang Bio Announces Pricing of $8 Million Public Offering - GlobeNewswire
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - Quantisnow
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - Insider Monkey
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering - Quantisnow
Passage Bio shares transition to Nasdaq Capital Market - Investing.com
Annovis Bio, Inc. Announces Proposed Public Offering - Quantisnow
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress - Yahoo Finance
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewswire
Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE) - Yahoo Finance UK
Cabaletta Bio Discloses Unaudited Cash and Cash Equivalents of $164 Million as of December 31, 2024 - Defense World
Palisade Bio Completes All Five SAD Cohorts and Advances to - GlobeNewswire
Vyant Bio (OTCMKTS:VYNT) Shares Up 7.8% – Time to Buy? - Defense World
Mustang Bio Announces Reverse Stock Split - GlobeNewswire
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Cadenza Bio, Inc. Announces Members of the Women's Health Scientific Advisory Board - Chicago Star Media
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
Pivot Bio Announces Ryan Degnan as Head of Growth - PR Newswire
Adicet Bio Provides Corporate Update - TradingView
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - The Bakersfield Californian
7 Best Biotech Stocks to Buy for 2025 | Investing - U.S News & World Report Money
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 - Seeking Alpha
Geode Capital Management LLC Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
KALA BIO Announces Private Placement Agreement with Institutional Investors - Defense World
KALA BIO Announces $10,750,000 Private Placement - GlobeNewswire
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds - Yahoo Finance
**BioAtla Updates Corporate Presentation in 8-K Filing** - Defense World
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases - Business Wire
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - GlobeNewswire
Annovis Bio 8-K Filing Reveals Investor Update and Presentation Details - Defense World
Hamps Bio share price hits 5% upper circuit after listing at 90% premium - Mint
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - Yahoo Finance
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt - The Manila Times
INmune Bio Strengthens Balance Sheet Ahead of Crucial Alzheimer's Trial Data, Clears $15M Debt - StockTitan
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Yahoo Finance
Hyderabad's Suven to acquire controlling stake in Princeton based NJ Bio, Inc - Deccan Herald
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
PRUDENTIAL FINANCIAL INC's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire
/C O R R E C T I O N -- Today's Marketplace/ - Quantisnow
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewswire
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Kronos Bio : Management Change/Compensation Form 8 K - Marketscreener.com
Attendee List for BevNET Live Winter 2024 - BevNET.com
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy - GlobeNewswire
Annovis to Host Year-End Investor Webcast on December 11, 2024 - Quantisnow
Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics - Yahoo Finance
GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) - The Manila Times
GRI Bio Showcases GRI-0621’s Potential to Reduce - GlobeNewswire
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):